Structure, function and antagonists of urokinase-type plasminogen activator

Frontiers in Bioscience

Volumn 14, Issue 10, 2009, Pages 3782-3794

  Carriero, Maria Vincenza ^a   Franco, Paola ^b   Vocca, Imma ^b   Alfano, Daniela ^b   Votta, Giuseppina ^b   Longanesi Cattani, Immacolata ^a   Bifulco, Katia ^a   Mancini, Alessandro ^c   Caputi, Mario ^c   Stoppelli, Maria Patrizia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Inhibitors of urokinase; Review; Serine protease; Urokinase

Indexed keywords

ENZYME INHIBITOR; UROKINASE;

CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVE SITE; HUMAN; KRINGLE DOMAIN; METABOLISM; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION;

CATALYTIC DOMAIN; ENZYME INHIBITORS; HUMANS; KRINGLES; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 63849262635     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2735/3488     Document Type: Article

References (112)

1. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., Skriver, L.: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44, 139-266(1985)
2. Andreasen, P. A., Kjoller, L., Christensen, L., Duffy, M. J.: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72, 1-22(1997) (Pubitemid 27314632)
3. List, K., Jensen, O. N., Bugge, T. H., Lund, L. R., Ploug, M., Dano, K., Behrendt, N.: Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry 39, 508-515(2000) (Pubitemid 30077624)
4. Moran, P., Li, W., Fan, B., Vij, R., Eigenbrot, C., Kirchhofer, D.: Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 281, 30439-30446(2006) (Pubitemid 44596152)
5. Franco, P., Iaccarino, C., Chiaradonna, F., Brandazza, A., Iavarone, C., Mastronicola, M. R., Nolli, M. L., Stoppelli, M. P.: Phosphorylation of pro-urokinase at Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adhesion and motility. J Cell Biol 137, 779-791(1997) (Pubitemid 27200677)
6. Buko, A. M., Kentzer, E. J., Petros, A., Menon, G., Zuiderweg, E. R., Sarin, V. K.: Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator. Proc Natl Acad Sci USA 88, 3992-3996(1991) (Pubitemid 21916750)
7. Rabbani, S. A., Mazar, A. P., Bernier, S. M., Haq, M., Bolivar, I., Henkin, J., Goltzman D.: Structural requirements for the growth factor activity of the aminoterminal domain of urokinase. J Biol Chem 267, 14151-14156(1992)
8. Riccio, A., Grimaldi, G., Verde, P., Sebastio, G., Boast, S., Blasi F.: The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res 13, 2759-2771(1985)
9. Tripputi, P., Blasi, F., Verde, P., Cannizzaro, L. A., Emanuel, B. S., Croce, C. M.: Human urokinase gene is located on the long arm of chromosome 10. Proc Natl Acad Sci USA 82, 4448-4452(1985) (Pubitemid 15234251)
10. Verde, P., Boast, S., Franzé, A., Robbiat, F., Blasi F.: An upstream enhancer and a negative element in the 5' flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 16, 10699-10716(1988)
11. Nerlov, C., De Cesare, D., Pergola, F., Caracciolo, A., Blasi, F., Johnsen, M., Verde, P.: A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 11, 4573-4582(1992)
12. Nagamine, Y., Medcalf, R. L., Muñoz-Cánoves, P.: Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 93, 661-675(2005) (Pubitemid 40485401)
13. Hansen, S. K., Nerlov, C., Zabel, U., Verde, P., Johnsen, M., Baeuerle, P. A., Blasi, F.: A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 11, 205-213(1992)
14. Tordai, H., Nagy, A., Farkas, K., Bányai, L., Patthy, L.: Modules, multidomain proteins and organismic complexity. FEBS J 272, 5064-5078(2005) (Pubitemid 41415127)
15. Hansen, A. P., Petros, A. M., Meadows, R. P., Nettesheim, D. G., Mazar, A. P., Olejniczak, E. T., Xu, R. X., Pederson, T. M., Henkin, J., Fesik, S. W.: Solution structure of the amino-terminal fragment of urokinasetype plasminogen activator. Biochemistry 33, 4847-4864(1994) (Pubitemid 24158434)
16. Appella, E., Robinson, E. A., Ullrich, S. J., Stoppelli, M. P., Corti, A., Cassani, G., Blasi, F.: The receptorbinding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 262, 4437-4440(1987) (Pubitemid 17102801)
17. Spraggon, G., Phillips, C., Nowak, U. K., Ponting, C. P., Saunders, D., Dobson, C. M., Stuart, D. I., Jones, E. Y.: The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 3, 681-691(1995)
18. Vassalli, J. D., Baccino D., Belin, D.: A cellular binding site for the Mr 55, 000 form of the human plasminogen activator, urokinase. J Cell Biol 100, 86-92(1985) (Pubitemid 15151884)
19. Stoppelli, M. P., Corti, A., Soffientini, A., Cassani, G., Blasi, F., Assoian, R. K.: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82, 4939-4943(1985) (Pubitemid 15249921)
20. Magdolen, V., Rettenberger, P., Koppitz, M., Goretzki, L., Kessler, H., Weidle, U. H., König, B., Graeff, H., Schmitt M., Wilhelm, O.: Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur J Biochem 237, 743-751(1996) (Pubitemid 26157664)
21. Bdeir, K., Kuo, A., Sachais, B. S., Rux, A. H., Bdeir, Y., Mazar, A., Higazi, A. A., Cines, D. B.: The kringle stabilizes urokinase binding to the urokinase receptor. Blood 102, 3600-3608(2003) (Pubitemid 37409377)
22. Cubellis, M. V., Nolli, M. L., Cassani, G., Blasi, F.: Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 261, 15819-15822(1986) (Pubitemid 17202819)
23. Ellis, V., Behrendt, N., Dano, K.: Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266, 12752-12758(1991) (Pubitemid 21907159)
24. Alfano, D., Franco, P., Vocca, I., Gambi, N., Pisa, V., Mancini, A., Caputi, M., Carriero, M. V., Iaccarino I., Stoppelli, M. P.: The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 93, 205-211(2005) (Pubitemid 40253723)
25. Alfano, D., Iaccarino, I., Stoppelli, M. P.: Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem 281, 17758-17767(2006) (Pubitemid 44035575)
26. Franco, P., Vocca, I., Carriero, M. V., Alfano, D., Cito, L., Longanesi-Cattani, I., Grieco, P., Ossowski, L., Stoppelli, M. P.: Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin. J Cell Sci 119, 3424-3434(2006) (Pubitemid 44405226)
27. Patthy, L.: Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 41, 657-663(1985)
28. Li, X., Bokman, A. M., Llinás, M., Smith, R. A., Dobson, C. M.: Solution structure of the kringle domain from urokinase-type plasminogen activator. J Mol Biol 235, 1548-1559(1994)
29. Stephens, R. W., Bokman, A. M., Myöhänen, H. T., Reisberg, T., Tapiovaara, H., Pedersen, N., Grøndahl-Hansen, J., Llinás, M., Vaheri, A.: Heparin binding to the urokinase kringle domain. Biochemistry 31, 7572-7579(1992)
30. Liang, O. D., Chavakis, T., Linder, M., Bdeir, K., Kuo, A., Preissner, K. T.: Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence. Biol Chem 384, 229-236(2003) (Pubitemid 36348322)
31. Tarui, T., Akakura, N., Majumdar, M., Andronicos, N., Takagi, J., Mazar, A. P., Bdeir, K., Kuo, A., Yarovoi, S. V., Cines, D. B., Takada, Y.: Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost 95, 524-534(2006)
32. Pluskota, E., Soloviev, D. A., Bdeir, K., Cines, D. B., Plow, E. F.: Integrin (alpha) M (beta) 2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem 279, 18063-18072(2004) (Pubitemid 38560576)
33. Mukhina, S., Stepanova, V., Traktouev, D., Poliakov, A., Beabealashvilly, R., Gursky, Y., Minashkin, M., Shevelev, A., Tkachuk, V.: The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J Biol Chem 275, 16450-16458(2000) (Pubitemid 30398865)
34. Wang, X. Q., Bdeir, K., Yarovoi, S., Cines, D. B., Fang, W., Abraham, E.: Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury. J Immunol 177, 5550-5557(2006) (Pubitemid 44527629)
35. Kim, K. S., Hong, Y. K., Joe, Y. A., Lee, Y., Shin, J. Y., Park, H. E., Lee, I. H., Lee, S. Y., Kang, D. K., Chang, S. I., Chung, S. I.: Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. J Biol Chem 278, 11449-11456(2003) (Pubitemid 36792704)
36. Franco, P., Massa, O., Garcia-Rocha, M., Chiaradonna, F., Iaccarino, C., Correas, I., Mendez, E., Avila, J., Blasi, F., Stoppelli, M. P.: Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J Biol Chem 273, 27734-27740(1998) (Pubitemid 28500500)
37. Guo, Y., Higazi, A. A., Arakelian, A., Sachais, B. S., Cines, D., Goldfarb, R. H., Jones, T. R., Kwaan, H., Mazar, A. P., Rabbani, S. A.: A peptide derived from the non receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14, 1400-1410(2000) (Pubitemid 30439749)
38. Andreasen, P. A., Egelund, R., Petersen, H. H.: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57, 25-40(2000) (Pubitemid 30105328)
39. van der Voort, R., Taher, T. E., Derksen, P. W., Spaargaren, M., van der Neut, R., Pals, S. T.: The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 79, 39-90(2000) (Pubitemid 30228120)
40. Cubellis, M. V., Wun, T. C., Blasi, F.: Receptormediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9, 1079-1085(1990)
41. Olson, D., Pöllänen, J., Høyer-Hansen, G., Rønne, E., Sakaguchi, K., Wun, T. C., Appella, E., Danø, K., Blasi, F.: Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267, 9129-9133(1992)
42. Hall, S. W., Humphries, J. E., Gonias, S. L.: Inhibition of cell surface receptor-bound plasmin by a2-antiplasmin and a2-macroglobulin. J Biol Chem 266, 12329-12336(1991) (Pubitemid 21907096)
43. Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, S., Blasi, F., Fazioli, F.: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15, 1572-1582(1996) (Pubitemid 26112379)
44. Carmeliet, P., Moons, L., Lijnen, R., Baes, M., Lemaitre, V., Tipping, P., Drew, A., Eeckhout, Y., Shapiro, S., Lupu, F., Collen, D.: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17, 439-444(1997) (Pubitemid 27518393)
45. Rømer, M. U., Kirkebjerg, D. A., Knud Larsen, J., Hofland, K. F., Christensen, I. J., Buhl-Jensen, P., Almholt, K., Lerberg Nielsen, O., Brünner, N., Lademann, U.: Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. Thromb Haemost 94, 859-866(2005) (Pubitemid 41489250)
46. Deshet, N., Lupu-Meiri, M., Espinoza, I., Fili, O., Shapira, Y., Lupu, R., Gershengorn, M. C., Oron, Y.: Plasminogen-induced aggregation of PANC-1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor-1. J Cell Physiol in press (2008)
47. Rifkin, D. B., Mazzieri, R., Munger, J. S., Noguera, I., Sung, J.: Proteolytic control of growth factor availability. APMIS 107, 80-85(1999) (Pubitemid 29133526)
48. Romer, J., Bugge, T. H., Pyke, C., Lund, L. R., Flick, M. J., Degen, J. L., Dano, K.: Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 2, 287-292(1996) (Pubitemid 26080649)
49. Schuster, V., Hügle, B., Tefs, K.: Plasminogen deficiency. J Thromb Haemost 12, 2315-2322(2007) (Pubitemid 350154337)
50. Watabe, T., Yoshida, K., Shindoh, M., Kaya, M., Fujikawa, K., Sato, H., Seiki, M., Ishii, S., Fujinaga, K.: The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 77, 128-137(1998) (Pubitemid 28308562)
51. Pulukuri, S. M., Rao, J. S.: Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res 67, 6637-6646(2007) (Pubitemid 47105509)
52. Nanbu, R., Menoud, P. A., Nagamine, Y.: Multiple instability-regulating sites in the 3' untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol 14, 4920-4928(1994)
53. Han, Q., Leng, J., Bian, D., Mahanivong, C., Carpenter, K. A., Pan, Z. K., Han, J., Huang, S.: Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. J Biol Chem 277, 48379-48385(2002) (Pubitemid 35470794)
54. Tran, H., Maurer, F., Nagamine, Y.: Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol 23, 7177-7188(2003) (Pubitemid 37211000)
55. Sengupta, S., Kim, K. S., Berk, M. P., Oates, R., Escobar, P., Belinson, J., Li, W., Lindner, D. J., Williams B., Xu, Y.: Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 26, 2894-2901(2007) (Pubitemid 46701441)
56. Kleiner, S., Faisal, A., Nagamine, Y.: Induction of uPA gene expression by the blockage of E-cadherin via Src-and Shc-dependent Erk signaling. FEBS J 274, 227-240(2007) (Pubitemid 44952911)
57. Myöhänen, H. T., Stephens, R. W., Hedman, K., Tapiovaara, H., Rønne, E., Høyer-Hansen, G., Danø, K., Vaheri, A.: Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem 41, 1291-1301(1993) (Pubitemid 23239093)
58. Andreasen, P. A.: PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets 8, 1030-1041(2007) (Pubitemid 47578151)
59. Chiaradonna, F., Fontana, L., Iavarone, C., Carriero, M. V., Scholz, G., Barone, M. V., Stoppelli, M. P.: Urokinase receptor-dependent and-independent p56/59 (hck) activation state is a molecular switch between myelomonocytic cell motility and adherence. EMBO J 18, 3013-3023(1999) (Pubitemid 29255610)
60. Medcalf, R. L., Stasinopoulos, S. J.: The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J 272, 4858-4867(2005) (Pubitemid 41415110)
61. Lluís, F., Roma, J., Suelves, M., Parra, M., Aniorte, G., Gallardo, E., Illa, I., Rodríguez, L., Hughes, S. M., Carmeliet, P., Roig, M., Muñoz-Cánoves, P.: Urokinasedependent plasminogen activation is required. Blood 97, 1703-1711(2001)
62. Heymans, S., Pauschinger, M., De Palma, A., Kallwellis-Opara, A., Rutschow, S., Swinnen, M., Vanhoutte, D., Gao, F., Torpai, R., Baker, A. H., Padalko, E., Neyts, J., Schultheiss, H. P., Van de Werf, F., Carmeliet P., Pinto, Y. M.: Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114, 565-2573(2006)
63. Zhou, H. M., Nichols, A., Meda, P., Vassalli, J. D.: Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 19, 4817-4826(2000)
64. Lund, L. R., Romer, J., Bugge, T. H., Nielsen, B. S., Frandsen, T. L., Degen, J. L., Stephens, R. W., Danø, K.: Functional overlap between two classes of matrixdegrading proteases in wound healing. EMBO J 18, 4645-4656(1999) (Pubitemid 29415519)
65. Bugge, T. H., Flick, M. J., Danton, M. J., Daugherty, C. C., Romer, J., Dano, K., Carmeliet, P., Collen D., Degen, J. L.: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93, 5899-5904(1996) (Pubitemid 26190774)
66. Falkenberg, M., Tom, C., DeYoung, M. B., Wen, S., Linnemann, R., Dichek, D. A.: Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci USA 99, 10665-10670(2002)
67. Kitching, A. R., Holdsworth, S. R., Ploplis, V. A., Plow, E. F., Collen, D., Carmeliet, P., Tipping, P. G.: Plasminogen and plasminogen activators protect against renal injury in crescentis glomerulonephritis. J Exp Med 185 963-968 (1997) (Pubitemid 27119880)
68. Mondino, A., Blasi, F.: uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25, 450-455(2004) (Pubitemid 38951087)
69. Gyetko, M. R., Sud, S., Chensue, S. W.: Urokinasedeficient mice fail to generate a type 2 immune response following schistosomal antigen challenge. Infect Immun 72, 461-467(2004) (Pubitemid 38018207)
70. Shapiro, R. L., Duquette, J. G., Nunes, I., Roses, D. F., Harris. M. N., Wilson. E. L., Rifkin, D. B.: Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am J Pathol 15, 359-369(1997) (Pubitemid 27027125)
71. Shapiro, R. L., Duquette, J. G., Roses, D. F., Nunes, I., Harris, M. N, Kamino, H., Wilson, E. L., Rifkin, D. B.: Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 56, 3597-3604(1996) (Pubitemid 26251658)
72. Almholt, K., Lund, L. R., Rygaard, J., Nielsen, B. S., Danø, K., Rømer, J., Johnsen, M.: Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 113, 525-532(2005) (Pubitemid 40038727)
73. Duffy, M. J.: Plasminogen activators and cancer. Blood Coagul Fibrinolysis 1, 681-687(1990)
74. Schmitt, M., Jänicke, F., Graeff, H.: Tumourassociated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis 1, 695-702(1990)
75. Del Vecchio, S., Stoppelli, M. P., Carriero, M. V., Fonti, R., Massa, O., Li, P. Y., Botti, G., Cerra, M., D'Aiuto, G., Esposito, G., Salvatore, M.: Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels1. Cancer Res 53, 3198-3206(1993) (Pubitemid 23210335)
76. Carriero, M. V., Franco, P., Del Vecchio, S., Massa, O., Botti, G., D'Aiuto, G., Stoppelli, M. P., Salvatore, M.: Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54, 5445-5454(1994) (Pubitemid 24336039)
77. Duffy, M. J., Duggan, C.: The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 37, 541-548(2004) (Pubitemid 38845017)
78. Silvestri, I., Longanesi Cattani, I., Franco, P., Pirozzi, G., Botti, G., Stoppelli, M. P., Carriero, M. V.: Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha (v) beta5 vitronectin receptor cell surface expression. Int J Cancer 102, 562-571(2002) (Pubitemid 35334462)
79. Mueller, M. M., Fusenig, N. E.: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4, 839-849(2004) (Pubitemid 39472951)
80. Bugge, T. H., Lund, L. R., Kombrinck, K. K., Nielsen, B. S., Holmbäck, K., Drew, F., Flick, M. J., Witte, D. P., Danø, K., Degen, J. L: Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16, 3097-3104(1998) (Pubitemid 28318780)
81. Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J. M., Noël, A.: The Plasminogen Activator Inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152, 777-784(2001) (Pubitemid 34280162)
82. Magdolen, V., Bürgle, M., de Prada, N. A., Schmiedeberg, N., Riemer, C., Schroeck, F., Kellermann, J., Degitz, K., Wilhelm, O. G., Schmitt, M., Kessler, H.: Cyclo19, 31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinasetype plasminogen activator with its receptor (CD87). Biol Chem 382, 1197-1205(2001) (Pubitemid 32894026)
83. Ploug, M., Østergaard, S., Gårdsvoll, H., Kovalski, K., Holst-Hansen, C., Holm, A., Ossowski L., Danø, K.: Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40, 12157-12168(2001) (Pubitemid 32946557)
84. Corti, A., Sarubbi, E., Soffientini, A., Nolli, M. L., Zanni, A., Galimberti, M., Parenti, F., Cassani, G.: Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase. Thromb Haemost 62, 934-939(1989) (Pubitemid 20005006)
85. Guo, Y., Mazar, A. P., Lebrun, J., Rabbani, S. A.: An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 62, 4678-4684(2002)
86. Mishima, K., Mazar, A. P., Gown, A., Skelly, M., Ji, X. D., Wang, X. D., Jones, T. R., Cavenee, W. K., Huang, H. J.: A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 97, 8484-8489(2000) (Pubitemid 30639699)
87. McGuire, P. G., Jones, T. R., Talarico, N., Warren E., Das, A.: The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci 44, 2736-2742(2003) (Pubitemid 36618438)
88. Berkenblit, A., Matulonis, U. A., Kroener, J. F., Dezube, B. J., Lam, G. N., Cuasay, L. C., Brunner, N., Jones, T. R., Silverman, M. H., Gold, M. A.: A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 99, 50-57(2005) (Pubitemid 41354582)
89. Dano, K., Nielsen, L. S., Moller, V., Engelhart, M.: Inhibition of a plasminogen activator from oncogenic virustransformed mouse cells by rabbit antibodies against the enzyme. Biochim Biophys Acta 630, 146-151(1980) (Pubitemid 10019442)
90. Ossowski, L., Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35, 611-619(1983) (Pubitemid 14168365)
91. Salerno, G., Verde, P., Nolli, M. L., Corti, A., Szöts, H., Meo, T., Johnson, J., Bullock, S., Cassani, G., Blasi, F.: Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor. Proc. Natl Acad Sci USA 81, 110-114(1984) (Pubitemid 14180837)
92. Petersen, H. H., Hansen, M., Schousboe, S. L., Andreasen, P. A.: Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme. Eur J Biochem 268, 4430-4439(2001) (Pubitemid 32862852)
93. Zeslawska, E., Schweinitz, A., Karcher, A., Sondermann, P., Sperl, S., Sturzebecher, J., Jacob, U.: Crystals of the urokinase type plasminogen activator variant beta (c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol 301, 465-475(2000)
94. Rockway, T. W., Nienaber, V., Girando, V. L.: Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Des 8, 2541-2558(2002) (Pubitemid 35331529)
95. Ke, S. H., Coombs, G. S., Tachias, K., Corey, D. R., Madison, E. L.: Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 272, 20456-20462(1997) (Pubitemid 27355599)
96. Tamura, S. Y., Weinhouse, M. I., Roberts, C. A., Goldman, E. A., Masukawa, K., Anderson, S. M., Cohen, C. R., Bradbury, A. E., Bernardino, V. T., Dixon, S. A., Ma, M. G., Nolan, T. G., Brunck, T. K.: Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Bioorg Med Chem Lett 10, 983-987(2000) (Pubitemid 30301608)
97. Schweinitz, A., Steinmetzer, T., Banke, I. J., Arlt, M. J., Sturzebecher, A., Schuster, O., Geissler, A., Giersiefen, H., Zeslawska, E., Jacob, U., Kruger, A., Sturzebecher, J.: Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 279, 33613-33622(2004) (Pubitemid 39063010)
98. Ertongur, S., Lang, S., Mack, B., Wosikowski, K., Muehlenweg, B., Gires, O.: Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 110, 815-824(2004) (Pubitemid 38758506)
99. Setyono-Han, B., Sturzebecher, J., Schmalix, W. A., Muehlenweg, B., Sieuwerts, A. M., Timmermans, M., Magdolen, V., Schmitt, M., Klijn, J. G., Foekens, J. A.: Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 93, 779-786(2005) (Pubitemid 40485417)
100. Fish, P. V., Barber, C. G., Brown, D. G., Butt, R., Collis, M. G., Dickinson, R. P., Henry, B. T., Horne, V. A., Huggins, J. P., King, E., O'Gara, M., McCleverty, D., McIntosh, F., Phillips, C., Webster, R.: Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7- sulfonamidoisoquinolinyl) guanidines. J Med Chem 50, 2341-2351(2007) (Pubitemid 46799246)
101. Killeen, S. D., Andrews, E. J., Wang, J. H., Wu, T., Schmalix, W., Muehlenweg, B., Redmond, H. P.: Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgeryaccelerated growth of murine metastases. Br J Cancer 96, 262-268(2007) (Pubitemid 46160631)
102. Zhu, M., Gokhale, V. M., Szabo, L., Munoz, R. M., Baek, H., Bashyam, S., Hurley, L. H., Von Hoff, D. D., Han, H.: Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther 6, 1348-1356(2007) (Pubitemid 46711998)
103. Hansen, M., Wind, T., Blouse, G. E., Christensen, A., Petersen, H. H., Kjelgaard, S., Mathiasen, L., Holtet, T. L., Andreasen, P. A.: A urokinase-type plasminogen activatorinhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J Biol Chem 280, 38424-38437(2005) (Pubitemid 43853740)
104. Andersen, L. M., Wind, T., Hansen, H. D., Andreasen, P. A.: A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: Changing species specificity by substitution of a single residue. Biochem J in press (2008)
105. Su, Y., Ortiz, J., Liu, S., Bugge, T. H., Singh, R., Leppla, S. H., Frankel, A. E.: Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice. Cancer Res 67, 3329-3336(2007) (Pubitemid 46724872)
106. de Fougerolles, A., Vornlocher, H. P., Maraganore, J., Lieberman, J.: Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6, 443-453(2007) (Pubitemid 47064567)
107. Arens, N., Gandhari, M., Bleyl, U., Hildenbrand, R.: In vitro suppression of urokinase plasminogen activator in breast cancer cells - a comparison of two antisense strategies. Int J Oncol 26, 113-119(2005)
108. Salvi, A., Arici, B., De Petro, G., Barlati, S.: Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 3, 671-678(2004) (Pubitemid 39193747)
109. Gondi, C. S., Kandhukuri, N., Dinh, D. H., Gujrati, M., Rao, J. S.: Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 31, 19-27(2007)
110. Pakneshan, P., Têtu, B., Rabbani, S. A.: Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res 10, 3035-3041(2004) (Pubitemid 38619680)
111. Pakneshan, P., Szyf, M., Farias-Eisner, R., Rabbani, S. A.: Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 279, 31735-31744(2004) (Pubitemid 39037845)
112. Zannetti, A., Del Vecchio, S., Romanelli, A., Scala, S., Saviano, M., Calì, G., Stoppelli, M. P., Pedone, C., Salvatore, M.: Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells. Biochem Pharmacol 70, 1277-1287(2005) (Pubitemid 41383463)